Piper Sandler raised the firm’s price target on CVS Health (CVS) to $74 from $72 and keeps an Overweight rating on the shares. The firm cites 2025 guidance calling for an 800 bps spread between Q1 2025 and Q4 2025 HCB segment MLR; and approximately 55% of 2025 adjusted EPS in the first half of the year and 45% in the second half.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CVS: